Sumitomo Life Insurance Co. boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,428 shares of the medical instruments supplier’s stock after buying an additional 440 shares during the period. Sumitomo Life Insurance Co.’s holdings in Becton, Dickinson and were worth $2,035,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Crestwood Advisors Group LLC bought a new stake in shares of Becton, Dickinson and during the first quarter worth approximately $101,000. North Star Investment Management Corp. raised its stake in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in shares of Becton, Dickinson and during the first quarter worth approximately $105,000. Parkside Financial Bank & Trust raised its stake in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Finally, Financial Architects Inc raised its stake in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the last quarter. Institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at 198.57 on Friday. The company has a market cap of $45.19 billion, a P/E ratio of 57.51 and a beta of 1.05. The stock has a 50 day moving average of $200.05 and a 200-day moving average of $189.42. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.35 EPS. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/27/sumitomo-life-insurance-co-has-2-04-million-stake-in-becton-dickinson-and-company-bdx.html.

BDX has been the topic of a number of research analyst reports. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Finally, Cowen and Company restated an “outperform” rating and set a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $195.79.

In other news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of Becton, Dickinson and stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,605 shares of company stock valued at $9,718,986. 1.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.